1:00 pm – 1:03 pm: A multicenter, observational study to evaluate corneal neurosensory abnormalities in patients with Sjögren’s dry eye. Scott Hauswirth, OD, FAAO

1:03 pm – 1:06 pm: Outcome Measures and Metrics Used and Clinical Results of Trials for Sjögren’s versus Non-Sjögren’s Dry Eye. Kyle Munar, BA

1:06 pm – 1:09 pm: Minimally invasive glaucoma surgery (MIGS) outcomes in uveitis - a retrospective single center study. Elisah Huynh, BS

1:09 pm – 1:12 pm: Uveitic Glaucoma Interest Group Recommendations for Uveitis-Related Ocular Hypertension and Glaucoma Management. David Chu, MD

1:12 pm – 1:15 pm: Resolution of refractory bilateral exudative retinal detachments with teprotumumab in a patient with thyroid eye disease and posterior scleritis. Dylann K. Fujimoto, MD

1:15 pm – 1:18 pm: Prospective validation of serial aqueous humor sampling for longitudinal ocular proteomics: safety results from the OPTICA trial in geographic atrophy. Tsai-Chu Yeh, MD, MTM

1:18 pm – 1:21 pm: The Gene Therapy Blind Spot: Video-Based Volumetric Analysis (V3xV) for Precision Subretinal Dosing. David RP Almeida, MD, MBA, PhD

1:21 pm – 1:24 pm: OCTA Imaging of Hyalocytes in Patients with Uveitis. James Samson

1:24 pm – 1:27 pm: Long-term follow-up of patients with persistent anterior uveitis after uncomplicated cataract surgery. Elyssa Dionne, BA

1:27 pm – 1:30 pm: Use of Immunomodulatory Treatment for Herpes Virus Associated Ocular Inflammation. Parvin Aghayeva, MD

1:30 pm – 1:33 pm: Dropless Cataract Surgery in Patients with Inflammatory Eye Disease. Symon Ma, MS4

1:33 pm – 1:36 pm: Retinal Vasculitis in Intermediate Uveitis: A Hidden Driver of Uveitis Flares. Andrew Briere, DO

1:36 pm – 1:39 pm: Ixoberogene soroparvovec (Ixo-vec) intravitreal gene therapy for neovascular age-related macular degeneration (nAMD): LUNA trial 2-year results.  Roger A. Goldberg, MD, MBA, Diana Do, MD

1:39 pm – 1:42 pm: Case of bilateral hyphema in a patient treated with Lutetium (177Lu) vipivotide tetraxetan (Pluvicto) for metastatic castration-resistant prostate cancer (mCRPC). Roger Henry, MD